Institution
Sarah Cannon
Also known as: SCRI
- 5running trials
- 6closed trials
- 5,762publications (OpenAlex)
Running trials
Recruiting
Recruiting
Active, not recruiting
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Recruiting
Recruiting
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer3 recruiting
- Cervical cancer1 recruiting
- Childhood cancers1 recruiting
- Colorectal cancer1 recruiting
- Endometrial cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Glioblastoma1 recruiting
- Head and neck cancer1 recruiting
- Ovarian cancer1 recruiting
- Pancreatic cancer1 recruiting
Closed trials
Terminated
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Terminated
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Completed
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Terminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Completed
Completed
Registry name variants (5)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Sarah Cannon
Nashville, Tennessee 37203
7 trials
Sarah Cannon Nashville
Nashville, Tennessee 37203
1 trial
Contact: Referral Coordinator
Sarah Cannon, SCRI Oncology Partners
Nashville, Tennessee 37203
1 trial
NCT04678648A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Contact: Michael Mann, MD
Sarah Cannon, Tennesse Oncology
Nashville, Tennessee 37203
1 trial
Tennessee Oncology Nashville (Sarah Cannon)
Nashville, Tennessee 37203
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
- Metastatic breast cancer33 works · 0 trials
- Brain metastases14 works · 0 trials
Institution data: ROR 014t21j89 (CC0-1.0)Updated 15 Nov 2026